×
AbCellera Biologics EBIT 2019-2024 | ABCL
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
AbCellera Biologics ebit from 2019 to 2024. Ebit can be defined as earnings before interest and taxes.
View More
AbCellera Biologics EBIT 2019-2024 | ABCL
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
AbCellera Biologics ebit from 2019 to 2024. Ebit can be defined as earnings before interest and taxes.
Related Stocks
Company Name
Market
Cap
AstraZeneca (AZN)
$228.2B
Amgen (AMGN)
$156.5B
Gilead Sciences (GILD)
$129.7B
Vertex Pharmaceuticals (VRTX)
$117.9B
Bristol Myers Squibb (BMY)
$109.4B
CSL (CSLLY)
$78.2B
GSK (GSK)
$75B
Regeneron Pharmaceuticals (REGN)
$73.6B
Argenex SE (ARGX)
$38.9B
Alnylam Pharmaceuticals (ALNY)
$33.2B
BioNTech SE (BNTX)
$28.7B
BeiGene (ONC)
$22.6B
Biogen (BIIB)
$20.1B
Illumina (ILMN)
$15.9B
Insmed (INSM)
$14.2B
Genmab (GMAB)
$14.1B
Genmab (GNMSF)
$13.9B
Incyte (INCY)
$13.6B
Intra-Cellular Therapies (ITCI)
$13.6B
Moderna (MRNA)
$12.7B
BioMarin Pharmaceutical (BMRN)
$12.4B
Swedish Orphan Biovitrum (BIOVF)
$10.9B
Vaxcyte (PCVX)
$10.5B
Bio-Techne Corp (TECH)
$10.4B
Sarepta Therapeutics (SRPT)
$10.3B
Exelixis (EXEL)
$9.8B
Exact Sciences (EXAS)
$9.1B
QIAGEN (QGEN)
$8.8B
Ascendis Pharma (ASND)
$8.7B
Bio-Rad Laboratories (BIO.B)
$8.7B